Lantheus - LNTH Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month target prices for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $110.00. On average, they expect the company's stock price to reach $98.33 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $28.89 at the beginning of the year. Since then, LNTH shares have increased by 163.9% and is now trading at $76.25.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our LNTH earnings forecast.

Lantheus Holdings, Inc. (NASDAQ:LNTH) released its quarterly earnings data on Thursday, August, 4th. The medical equipment provider reported $0.81 EPS for the quarter, topping the consensus estimate of $0.64 by $0.17. The medical equipment provider had revenue of $223.80 million for the quarter, compared to analysts' expectations of $204.51 million. Lantheus had a net margin of 4.88% and a trailing twelve-month return on equity of 28.88%. Lantheus's quarterly revenue was up 121.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 earnings per share.

Lantheus issued an update on its third quarter 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of $0.80-$0.85 for the period, compared to the consensus estimate of $0.69. The company issued revenue guidance of $220.00 million-$230.00 million, compared to the consensus revenue estimate of $204.57 million.

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $76.25.

Lantheus (NASDAQ:LNTH) has a market capitalization of $5.24 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $0.43 on an earnings per share basis.

The company employs 612 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.